荷兰Agendia 
Agendia是开发基于基因表达分析的诊断工具的全球领导企业。公司关注使用肿瘤基因表达分析的诊断化验工具的开发与商业化。Agendia率先对于预后检验——MammaPrint®——进行了商业化，从而能够预测乳腺癌重发的机率。Agendia的产品线最近又新增了发现未知癌瘤的CupPrint®检验。Agendia与荷兰癌症研究院(NKI)保持着密切联系，从而能够接触到癌症研究的最新发展。在开发出了新型癌症诊断技术之后，Agendia将会发挥它的专家技术，为那些关注治癌新药开发的企业寻找想要的新基因表达式。

In 2008, Agendia launches its diagnostic test TargetPrint for breast cancer patients, which allows to obtain highly reliable quantitative data about each patients breast tumor and adds a secure prognostic tool for future treatment.

Leveraging the benefits of gene expression profiling
- microarray technology – and collaboration
The leaders of Agendia are the inventors and initiators of diagnostic microarray testing - the technology which forms the basis for the company’s commercially available tests.
Clinically-relevant tumor gene expression profiles are established through in-house research, research collaborations and strategic alliances with leading academic institutes. In particular, Agendia has very close links, both geographically and collaboratively, with The Netherlands Cancer Institute.

Once validated, these profiles are used to develop commercially available tests utilizing the microarray technology. Tests are currently performed in a high quality clinical laboratory at the company’s headquarters in Amsterdam, The Netherlands.

A growing business
Agendia working to develop further tests and applications and to market the current test portfolio globally through direct sales and an expanding distribution network. Both MammaPrint and CupPrint* are CE-marked and the company is ISO 17025 and CLIA accredited.
*